Arena Pharmaceuticals Stock News

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th

How this Week’s Premium Top 10 Performed, April 3, 2020 Posted by Greg Harmon on April 3rd, 2020 Each week I post the performance of the stocks that were given to subscribers the previous Sunday. Al

Merck recently announced upbeat data from Keytruda in colorectal cancer. Arena reported positive etrasimod data. Immunomedics slumps on possible delay of its cl

Envestnet Asset Management Inc. lowered its holdings in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 8.2% in the fourth quarter, according to the company in its most recent 13F filing with t

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arena Pharma (ARNA) and Ascendis Pharma (ASND) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arena Pharma

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perrigo Company (PRGO), Arena Pharma (ARNA) and Zymeworks (ZYME).

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perrigo Company ( PRGO – Research Report ), Arena Pharma ( ARNA – Research Report ) and Zymeworks ( ZYME – Resea

Advisor Group Inc. cut its stake in shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 27.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission

Arena Pharmaceuticals (NASDAQ:ARNA) is stoked over topline data from a Phase 1 clinical trial evaluating controlled-release (CR) delivery profiles of lead drug etrasimod.Results showed that CR

Arena Pharmaceuticals Inc:

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced positive topline data from a Phase 1 clinical study evaluating controlled-release delivery profiles (CR) for its investigational agent, etras

Arena Pharmaceuticals' etrasimod shows heart rate effect reduction in Phase 1 ARNA

Advisors Asset Management Inc. lowered its position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) by 8.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securiti